The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.
News about Johnson & Johnson
A jury cleared them of felonies but convicted on 10 misdemeanor counts.
Copycats of AbbVie's Humira and Amgen's Enbrel may soon win FDA approval.
It's like Brexit never even happened.
Videos about Johnson & Johnson
Hate New Year's resolutions? These Most Powerful Women tell their tips and tricks to ring in the New Year the right way.